Fibrinogen and Fibrin
- PMID: 33252741
- DOI: 10.1007/978-3-030-58971-4_15
Fibrinogen and Fibrin
Abstract
Fibrinogen is a large glycoprotein, synthesized primarily in the liver. With a normal plasma concentration of 1.5-3.5 g/L, fibrinogen is the most abundant blood coagulation factor. The final stage of blood clot formation is the conversion of soluble fibrinogen to insoluble fibrin, the polymeric scaffold for blood clots that stop bleeding (a protective reaction called hemostasis) or obstruct blood vessels (pathological thrombosis). Fibrin is a viscoelastic polymer and the structural and mechanical properties of the fibrin scaffold determine its effectiveness in hemostasis and the development and outcome of thrombotic complications. Fibrin polymerization comprises a number of consecutive reactions, each affecting the ultimate 3D porous network structure. The physical properties of fibrin clots are determined by structural features at the individual fibrin molecule, fibrin fiber, network, and whole clot levels and are among the most important functional characteristics, enabling the blood clot to withstand arterial blood flow, platelet-driven clot contraction, and other dynamic forces. This chapter describes the molecular structure of fibrinogen, the conversion of fibrinogen to fibrin, the mechanical properties of fibrin as well as its structural origins and lastly provides evidence for the role of altered fibrin clot properties in both thrombosis and bleeding.
Keywords: Fibrin; Fibrinogen; Hemostasis; Thrombosis; Viscoelastic polymer.
References
-
- Allan P, Uitte de Willige S, Abou-Saleh RH, Connell SD, Ariens RA (2012) Evidence that fibrinogen gamma’ directly interferes with protofibril growth: implications for fibrin structure and clot stiffness. J Thromb Haemost 10(6):1072–1080. https://doi.org/10.1111/j.1538-7836.2012.04717.x - DOI - PubMed
-
- Altieri DC, Agbanyo FR, Plescia J, Ginsberg MH, Edgington TS, Plow EF (1990) A unique recognition site mediates the interaction of fibrinogen with the leukocyte integrin Mac-1 (CD11b/CD18). J Biol Chem 265(21):12119–12122 - DOI
-
- Ariens RA (2013) Fibrin(ogen) and thrombotic disease. J Thromb Haemost 11(Suppl 1):294–305. https://doi.org/10.1111/jth.12229 - DOI - PubMed
-
- Blombäck B, Hessel B, Hogg D, Therkildsen L (1978) A two-step fibrinogen–fibrin transition in blood coagulation. Nature 275(5680):501–505. https://doi.org/10.1038/275501a0 - DOI - PubMed
-
- Bolliger D, Seeberger MD, Tanaka KA (2012) Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev 26(1):1–13. https://doi.org/10.1016/j.tmrv.2011.07.005 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
